Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Chongqing Upgra Biotechnology Co. Ltd. currently oversees 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 3 distinct examiners and 3 distinct art units, showing a complete lack of concentration in the prosecution of this portfolio. CARR, DEBORAH D is identified as the busiest examiner, currently managing 1 pending office action. This distribution means that each pending matter is being evaluated in a unique administrative environment by a different individual.
The involvement of 3 distinct art units indicates that the company's innovations in Biotechnology & Pharmaceuticals are being categorized into several different technical specialties. For the practitioner, this diversity requires a versatile strategy, as each of the 3 distinct examiners will likely have different approaches to patentability and prior art. There is no central examiner or art unit whose trends can be used to predict the outcomes for the rest of the portfolio.
With CARR, DEBORAH D handling only 1 pending office action, their influence is limited to a portion of the current workload. The practitioner must prepare for three separate prosecution tracks, each with its own set of examiner preferences and art unit norms. This decentralized structure for 3 pending office actions suggests that the portfolio's success depends on the ability to navigate multiple distinct examination styles simultaneously for Chongqing Upgra Biotechnology Co. Ltd.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CARR, DEBORAH D | 1 | 81.8% | +2.7% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016909 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CARR, DEBORAH D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18016897 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | NIEBAUER, RONALD T | — |
| 17779732 | POLYETHYLENE GLYCOL CONJUGATE DRUG, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JONES, DAMERON LEVEST | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1658 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18016909 | POLYETHYLENE GLYCOL CONJUGATE DRUG, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CARR, DEBORAH D | 1699 | §103§112 | Non-Final OA | — | Pending | Jan 19, 2023 |
| 18016897 | POLYETHYLENE GLYCOL CONJUGATE DRUG SYNERGIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | NIEBAUER, RONALD T | 1658 | §103§112DP | Non-Final OA | — | Pending | Jan 19, 2023 |
| 17779732 | POLYETHYLENE GLYCOL CONJUGATE DRUG, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JONES, DAMERON LEVEST | 1618 | §112 | Non-Final OA | — | Pending | May 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial